These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27399694)

  • 1. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.
    Guo M; Luo G; Liu C; Cheng H; Lu Y; Jin K; Liu Z; Long J; Liu L; Xu J; Huang D; Ni Q; Yu X
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Surgical therapy of pancreatic cancer - 5 years survival].
    Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
    Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma.
    Wang L; Wu H; Wang L; Lu J; Duan H; Liu X; Liang Z
    Diagn Pathol; 2016 Jul; 11(1):60. PubMed ID: 27391842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
    Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Cros J; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Eur J Cancer; 2013 Aug; 49(12):2643-53. PubMed ID: 23726265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
    Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
    Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.
    Fukumoto T; Watanabe T; Hirai I; Kimura W
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):472-9. PubMed ID: 27246905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
    Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
    HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
    Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
    EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
    Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
    HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
    Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
    Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
    Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
    JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.
    Lewis R; Drebin JA; Callery MP; Fraker D; Kent TS; Gates J; Vollmer CM
    HPB (Oxford); 2013 Jan; 15(1):49-60. PubMed ID: 23216779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
    Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
    Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer.
    Abe T; Ohuchida K; Endo S; Ookubo F; Mori Y; Nakata K; Miyasaka Y; Manabe T; Ohtsuka T; Nagai E; Oda Y; Nakamura M
    Surgery; 2017 Apr; 161(4):951-958. PubMed ID: 27939334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
    JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.